Cancer Tissue Diagnostics Market

Cancer Tissue Diagnostics Market: North America to Retain Its Dominance Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016 - 2026

The global cancer tissue diagnostics market is poised to grow from close to US$ 4,350 Mn in 2016 to nearly US$ 9,650 Mn by 2026 end. This represents a CAGR of 8.3% over the forecast period. The global market for cancer tissue diagnostics represents incremental opportunity of about US$ 5,300 Mn between 2016 and 2026.

Global Cancer Tissue Diagnostics Market Attractiveness Analysis by Region, 2016 – 2026

North America dominated the global cancer tissue diagnostics market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. North America accounted for 36.5% value share in 2016 and is projected to account for more than 40% share by 2026 end. In terms of value, APEJ is expected to register a CAGR of 8.0% during the forecast period. Despite a low value CAGR of 5.7%, the MEA cancer tissue diagnostics market is projected to grow 1.9X over 2016–2026.

cancer tissue diagnostics market

Constantly growing list of cancer biomarkers boosting the cancer tissue diagnostics market

Sheer number of biomarkers that can be utilised for early cancer detection from blood or plasma samples are constantly increasing, which is expected to bring new cancer biomarker tests in the market in the near future. For instance, researchers at the University of Sheffield have recently identified over 700 new blood biomarkers that can be used for early cancer detection. As per OECD statistics, the global biomarkers market for companion diagnostics was valued at about US$ 8.4 Bn in 2016. The growth in companion diagnostics is indicative of acceptance of biomarkers in healthcare systems and may offer attractive incentives for biomarkers business development.

Advanced diagnostics at reduced costs aiding the global cancer tissue diagnostics market

After the completion of the human genome project in 2003, cost of assembling one genome has reduced tremendously and also cut down the time of analysis with development of highly advanced sequencing equipment. For instance, in January 2014, Illumina Inc. launched HighSeq X Ten Sequencer, which cut down the cost of genome sequencing to as low as US$ 1,000 including reagents cost and sample preparation equipment depreciation cost. Further advancements may continue to push down the cost for less than the cost of an X-ray, which would enhance the accessibility of this technology and thus drive the growth of the market. This also facilitates the use of highly advanced technologies by smaller research and clinical laboratories that possess less technical expertise and low resources.

Enormous R&D investment poses a threat to the expansion of the cancer tissue diagnostics market

Development of all high end instruments such as PET, MRI, SPECT equipment as well as next-generation sequencing platforms, analytical instruments used for laboratory analysis of cancer specimen etc. need huge investments of time and money, which is expected to be the prime factor impacting the cancer tissue diagnostics market. Also, all big pharmaceutical companies are entering into the diagnostics business and are thus cutting down the growth prospects of diagnostic giants such as Roche, Danaher etc. If at all a company develops innovative diagnostic testing, they still have to invest in expensive clinical utility studies, and there is no guarantee that the product will get coverage.

Meeting the needs of hospital laboratories presents a significant opportunity for the growth of the global cancer tissue diagnostics market

Due to healthcare cost containment in majority of mature markets, hospital based laboratories are facing pressure to supply more services at reduced costs. Healthcare facilities are facing increased aging population and rising prevalence of chronic diseases. By 2018, almost 10% of the global population will be 65 and above. Also global healthcare spending is expected to witness 5.2% growth every year till 2018. This imposes cost management pressure on diagnostic labs. Thus, several laboratories have started adapting informatics solutions, which helps them to increase overall productivity with existing resources. In line with this, manufacturers of diagnostic tests can grab the opportunity to provide complementary services and support. For instance, Abbott laboratories recently launched AlinIQ support and services to help their laboratory partners manage operations to maximise throughput and capacity.

Report Description

Future Market Insights in its latest report titled ‘Cancer Tissue Diagnostics Market: Global Industry Analysis & Opportunity Assessment, 2016 – 2026’ gives a comprehensive assessment of the global cancer tissue diagnostics market. The report starts with an executive summary that gives a concise overview of the cancer tissue diagnostics market along with key market numbers and most important segment and regions. Also, important trends, drivers and restraints governing the cancer tissue diagnostics market are given so that the report audiences get an overview of the market dynamics operating in this market. In addition, a list of key market players operating in the cancer tissue diagnostics market is given, which are dealt individually in the competitive landscape section. In the executive summary, there is also a section devoted to the global cancer tissue diagnostics market revenue share by region for the year 2015.

A section of the report is devoted to explaining the market definitions of the cancer tissue diagnostics market by various types of cancer treatment detection. Different cancer types considered in the scope of the global cancer tissue diagnostics market report include breast cancer, lung cancer, colorectal cancer, melanoma, blood cancers (Hodgkin & non-Hodgkin lymphoma, leukemia, myeloma etc.), prostate cancer, ovarian cancer, stomach cancer and liver cancer. The diagnostic tests considered in the report include screening tests and confirmatory tests for all the cancer types mentioned above. However, the report excludes cancer diagnostic tests performed to diagnose the relapse of cancer. The next section of the report covers the market taxonomy of the cancer tissue diagnostics market.

Market Taxonomy

By Test Type

By Region

Immunohistochemistry (IHC) Test

In Situ Hybridisation Test

 

  • North America

  • Latin America

  • Western Europe

  • Eastern Europe

  • Asia Pacific excluding Japan

  • Middle East and Africa

  • Japan

  • Breast Cancer

  • Lung Cancer

  • Stomach Cancer

  • Colorectal Cancer

  • Prostate Cancer

  • Others

  • Breast Cancer

  • Non-Small Cell Lung Cancer

  • Bladder Cancer

  • Others

After the market taxonomy, there is a section of the report devoted to the cancer tissue diagnostics market analysis scenario. This section contains an overview of the cancer tissue diagnostics market and also gives the global cancer tissue diagnostics market value analysis and forecast from the year 2015 till the year 2026 with values given in US$ Mn. The year-on-year growth and the absolute dollar opportunity is also stated in this section of the report. Subsequent to this section, there is a section of the report totally devoted to studying in detail the market dynamics operating in the global cancer tissue diagnostics market. These market dynamics are in the form of macroeconomic indicators, supply side drivers, demand side drivers, restraints, opportunities and trends. This is an important section of the report as it gives the report audience a clear and a comprehensive picture regarding the direction where the market is heading, what are the main opportunities in the market, which factors are encouraging the expansion of the market and which factors are hampering the growth of the market.

After this section, regional epidemiology data is given for all the seven regions as mentioned in the market taxonomy. A section of the report states the cancer tissue diagnostics regulatory and reimbursement scenario. An important section of the report covers the Porter’s analysis which examines the supplier power, buyer power, entry threats and threat of substitutes and also analyses the degree of competition in the global cancer tissue diagnostics market. The report goes on to list the cancer tissue diagnostics market analysis and forecast by test type and by region. These important sections of the report list the Basis Point Share analysis, year-on-year growth analysis, absolute dollar opportunity and market attractiveness analysis.

In addition to the above mentioned sections, there is an entire section of the report devoted to study the competition landscape of the global cancer tissue diagnostics market. This type of information is important for both established players and new entrants in the cancer tissue diagnostics market in order to identify their main source of competition and study such companies deeply in order to assess their strong points. Each of the important players operating in the global cancer tissue diagnostics market is discussed individually and key information regarding these selected companies is given. The information includes insights on company details, company overview, business overview, etc. Key financial information and revenue, operating and net margins of these companies is also presented in the competition landscape. Last but not the least, a SWOT analysis of all the companies is presented in the competition landscape that discusses the strengths, weaknesses, opportunities and threats that the companies are facing in the cancer tissue diagnostics market. In addition, key developments related to the companies and their strategic overview is also given to provide readers a deep insight regarding the direction where important companies in the cancer tissue diagnostics market are headed. 

Research Methodology

Overall market size has been analysed through historical data, primary responses, and public domain data. Revenue of companies in the global cancer tissue diagnostics market has been benchmarked to ascertain the market size for the base year. Macroeconomic indicators such as GDP and end-use application industries’ growth have been considered to forecast the market size over the forecast period. Historical data, market participants’ performance, as well as the present macro-economic outlook has been taken into consideration for estimating the overall market trend forecast. This data is then validated using the triangulation method and is extensively scrutinised using advanced tools to garner quantitative and qualitative insights into the global cancer tissue diagnostics market.  

Table Of Content

1. Executive Summary

2. Cancer Tissue Diagnostics Introduction

2.1. Cancer Tissue Diagnostics Definition

2.2. Cancer Tissue Diagnostics Taxonomy

3. Cancer Tissue Diagnostics Analysis Scenario

3.1. Cancer Tissue Diagnostics Size (US$ Mn) and Forecast

3.1.1. Market Size and Y-o-Y Growth

3.1.2. Absolute $ Opportunity

4. Cancer Tissue Diagnostics Analysis Scenario

4.1. Macro-economic Factors

4.2. Drivers

4.2.1. Supply Side

4.2.2. Demand Side

4.3. Restraints

4.4. Opportunity

4.5. Trends

4.6. Cancer Epidemiology

4.7. Cancer Tissue Diagnostics Regulatory and Reimbursement Scenario

4.8. Porter’s Analysis

5. Global Cancer Tissue Diagnostics Analysis and Forecast, By Test Type

5.1. Introduction

5.1.1. Basis Point Share (BPS) Analysis By Test Type

5.1.2. Y-o-Y Growth Projections By Test Type

5.2. Market Size (US$ Mn) Forecast By Test Type

5.2.1. Immunohistochemical (IHC) Test

5.2.1.1. Breast Cancer

5.2.1.2. Stomach (gastric) Cancer

5.2.1.3. Colorectal Cancer

5.2.1.4. Prostate Cancer

5.2.1.5. Others

5.2.2. In situ hybridization (ISH) Test

5.2.2.1. Breast Cancer

5.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

5.2.2.3. Bladder Cancer

5.2.2.4. Others

5.3. Market Attractiveness Analysis By Test Type

6. Global Cancer Tissue Diagnostics Analysis and Forecast, By Region

6.1. Introduction

6.1.1. Basis Point Share (BPS) Analysis By Region

6.1.2. Y-o-Y Growth Projections By Region

6.2. Market Size (US$ Mn) Forecast By Region

6.2.1. North America

6.2.2. Western Europe

6.2.3. Asia Pacific Excl. Japan (APEJ)

6.2.4. Japan

6.2.5. Latin America

6.2.6. Eastern Europe

6.2.7. Middle East and Africa (MEA)

6.3. Market Attractiveness Analysis By Region

7. North America Cancer Tissue Diagnostics Analysis and Forecast

7.1. Introduction

7.1.1. Basis Point Share (BPS) Analysis

7.1.2. Y-o-Y Growth Projections

7.2. Market Size (US$ Mn) Forecast By Test Type

7.2.1. Immunohistochemical (IHC) Test

7.2.1.1. Breast Cancer

7.2.1.2. Stomach (gastric) Cancer

7.2.1.3. Colorectal Cancer

7.2.1.4. Prostate Cancer

7.2.1.5. Others

7.2.2. In situ hybridization (ISH) Test

7.2.2.1. Breast Cancer

7.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

7.2.2.3. Bladder Cancer

7.2.2.4. Others

7.3. Market Value Forecast By Country, 2016–2026

7.3.1. United States

7.3.2. Canada

7.4. Market Attractiveness Analysis

7.4.1. By Test Type

7.4.2. By Country

8. Latin America Cancer Tissue Diagnostics Analysis and Forecast

8.1. Introduction

8.1.1. Basis Point Share (BPS) Analysis

8.1.2. Y-o-Y Growth Projections

8.2. Market Size (US$ Mn) Forecast By Test Type

8.2.1. Immunohistochemical (IHC) Test

8.2.1.1. Breast Cancer

8.2.1.2. Stomach (gastric) Cancer

8.2.1.3. Colorectal Cancer

8.2.1.4. Prostate Cancer

8.2.1.5. Others

8.2.2. In situ hybridization (ISH) Test

8.2.2.1. Breast Cancer

8.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

8.2.2.3. Bladder Cancer

8.2.2.4. Others

8.3. Market Value Forecast By Country, 2016–2026

8.3.1. Brazil

8.3.2. Mexico

8.3.3. Rest of Latin America

8.4. Market Attractiveness Analysis

8.4.1. By Test Type

8.4.2. By Country

9. Western Europe Cancer Tissue Diagnostics Analysis and Forecast

9.1. Introduction

9.1.1. Basis Point Share (BPS) Analysis

9.1.2. Y-o-Y Growth Projections

9.2. Market Size (US$ Mn) Forecast By Test Type

9.2.1. Immunohistochemical (IHC) Test

9.2.1.1. Breast Cancer

9.2.1.2. Stomach (gastric) Cancer

9.2.1.3. Colorectal Cancer

9.2.1.4. Prostate Cancer

9.2.1.5. Others

9.2.2. In situ hybridization (ISH) Test

9.2.2.1. Breast Cancer

9.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

9.2.2.3. Bladder Cancer

9.2.2.4. Others

9.3. Market Value Forecast By Country, 2016–2026

9.3.1. UK

9.3.2. France

9.3.3. Germany

9.3.4. Spain

9.3.5. Italy

9.3.6. Rest of Western Europe

9.4. Market Attractiveness Analysis

9.4.1. By Test Type

9.4.2. By Country

10. Eastern Europe Cancer Tissue Diagnostics Analysis and Forecast

10.1. Introduction

10.1.1. Basis Point Share (BPS) Analysis

10.1.2. Y-o-Y Growth Projections

10.2. Market Size (US$ Mn) Forecast By Test Type

10.2.1. Immunohistochemical (IHC) Test

10.2.1.1. Breast Cancer

10.2.1.2. Stomach (gastric) Cancer

10.2.1.3. Colorectal Cancer

10.2.1.4. Prostate Cancer

10.2.1.5. Others

10.2.2. In situ hybridization (ISH) Test

10.2.2.1. Breast Cancer

10.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

10.2.2.3. Bladder Cancer

10.2.2.4. Others

10.3. Market Value Forecast By Country, 2016–2026

10.3.1. Russia

10.3.2. Poland

10.3.3. Rest of Eastern Europe

10.4. Market Attractiveness Analysis

10.4.1. By Test Type

10.4.2. By Country

11. Asia Pacific Excl. Japan (APEJ) Cancer Tissue Diagnostics Analysis and Forecast

11.1. Introduction

11.1.1. Basis Point Share (BPS) Analysis

11.1.2. Y-o-Y Growth Projections

11.2. Market Size (US$ Mn) Forecast By Test Type

11.2.1. Immunohistochemical (IHC) Test

11.2.1.1. Breast Cancer

11.2.1.2. Stomach (gastric) Cancer

11.2.1.3. Colorectal Cancer

11.2.1.4. Prostate Cancer

11.2.1.5. Others

11.2.2. In situ hybridization (ISH) Test

11.2.2.1. Breast Cancer

11.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

11.2.2.3. Bladder Cancer

11.2.2.4. Others

11.3. Market Value Forecast By Country, 2016–2026

11.3.1. China

11.3.2. Australia

11.3.3. India

11.3.4. ASEAN

11.3.5. Rest of APEJ

11.4. Market Attractiveness Analysis

11.4.1. By Test Type

11.4.2. By Country

12. Japan Cancer Tissue Diagnostics Analysis and Forecast

12.1. Introduction

12.1.1. Basis Point Share (BPS) Analysis

12.1.2. Y-o-Y Growth Projections

12.2. Market Size (US$ Mn) Forecast By Test Type

12.2.1. Immunohistochemical (IHC) Test

12.2.1.1. Breast Cancer

12.2.1.2. Stomach (gastric) Cancer

12.2.1.3. Colorectal Cancer

12.2.1.4. Prostate Cancer

12.2.1.5. Others

12.2.2. In situ hybridization (ISH) Test

12.2.2.1. Breast Cancer

12.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

12.2.2.3. Bladder Cancer

12.2.2.4. Others

12.3. Market Attractiveness Analysis

12.3.1. By Test Type

13. MEA Cancer Tissue Diagnostics Analysis and Forecast

13.1. Introduction

13.1.1. Basis Point Share (BPS) Analysis

13.1.2. Y-o-Y Growth Projections

13.2. Market Size (US$ Mn) Forecast By Test Type

13.2.1. Immunohistochemical (IHC) Test

13.2.1.1. Breast Cancer

13.2.1.2. Stomach (gastric) Cancer

13.2.1.3. Colorectal Cancer

13.2.1.4. Prostate Cancer

13.2.1.5. Others

13.2.2. In situ hybridization (ISH) Test

13.2.2.1. Breast Cancer

13.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

13.2.2.3. Bladder Cancer

13.2.2.4. Others

13.3. Market Value Forecast By Country, 2016–2026

13.3.1. GCC Countries

13.3.2. South Africa

13.3.3. Rest of MEA

13.4. Market Attractiveness Analysis

13.4.1. By Test Type

13.4.2. By Country

14. Competition Landscape

14.1. Competition Dashboard

14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

14.2.1. Abbott Laboratories

14.2.2. F. Hoffmann-La Roche Ltd. 

14.2.3. Thermo Fisher Scientific Inc.

14.2.4. Ventana Medical Systems, Inc

14.2.5. Bio Rad Laboratories Inc.

14.2.6. Enzo Life Sciences, Inc. 

14.2.7. Abcam plc.

14.2.8. BioGenex

14.2.9. Cell Signaling Technology, Inc.

14.2.10. Agilent Technologies, Inc.

14.2.11. PerkinElmer Inc. 

14.2.12. Bio SB

14.2.13. Cancer Genetics Inc.

14.2.14. Danaher Corporation

14.2.15. ROSETTA GENOMICS

14.2.16. Nanoprobes, Inc.,

14.2.17. Creative-Biolabs

14.2.18. Enzo Life Sciences, Inc

14.2.19.Sigma-Aldrich Co. LLC 

15. Assumptions and Acronyms Used

16.Research Methodology

List of Tables

Table 1: Global Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 2: Global Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Region, 2015 – 2026

Table 3: North America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 4: North America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 5: Latin America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 6: Latin America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 7: Western Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 8: Western Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

The market is expected to sTable revenue growth over the forecast period fuelled by demand for breast & lung cancer detection

Table 9: Eastern Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 10: Eastern Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 11: APEJ Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 12: APEJ Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Regional market revenue growth for both tests is expected to remain sTable over the forecast period, given rising demand

Table 13: Japan Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

Table 14: MEA Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026

Table 15: MEA Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026

List of Figures

Figure 1 : Global Cancer Tissue Diagnostics Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026

Figure 2 : Global Cancer Tissue Diagnostics Market Absolute $ Opportunity, 2016–2026

Figure 3: Global Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 4: Global Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026 

Figure 5: Global Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 6: Global Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026 

Figure 7: Global Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026 

Figure 8: Global Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026 

Figure 9: Global Cancer Tissue Diagnostics Market Share Analysis (%) By Region, 2016 & 2026

Figure 10: Global Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Region, 2015–2026 

Figure 11: North America Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 12: Latin America Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 13: Western Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 14: Eastern Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 15: APEJ Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 16: Japan Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 17: MEA Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 18: Global Cancer Tissue Diagnostics Market Attractiveness Analysis By Region, 2016–2026 

Figure 19: North America Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016, 2026

Figure 20: North America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026 

Figure 21: North America Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 22: North America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026 

Figure 23: North America Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 24: North America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026 

Figure 25: U.S. Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 26: Canada Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 27: North America Cancer Tissue Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026 

Figure 28: North America Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026 

Figure 29: North America Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026 

Figure 30: Latin America Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

Figure 31: Latin America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026 

Figure 32: Latin America Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 33: Latin America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026 

Figure 34: Latin America Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 35: Latin America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026 

Figure 36: Brazil Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 37: Mexico Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 38: Rest of Latin America Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 39: Latin America Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026 

Figure 40: Latin America Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026 

Figure 41: Latin America Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026 

Figure 42: Western Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

Figure 43: Western Europe Cancer Tissue Diagnostics Market

Figure 44: Western Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 45: Western Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026 

Figure 46: Western Europe Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 47: Western Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026 

Figure 48: Germany Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 49: Italy Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 50: France Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 51: U.K. Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 52: Spain Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 53: Rest Of Western Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 54: Western Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026 

Figure 55: Western Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026 

Figure 56: Western Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026 

Figure 57: Eastern Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

Figure 58: Eastern Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026 

Figure 59: Eastern Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 60: Eastern Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026 

Figure 61: Eastern Europe Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 62: Eastern Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026 

Figure 63: Poland Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 64: Russia Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 65: Rest of Eastern Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 66: Eastern Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026 

Figure 67: Eastern Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026 

Figure 68: Eastern Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026 

Figure 69: APEJ Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016 & 2026

Figure 70: APEJ Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026 

Figure 71: APEJ Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 72: APEJ Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026 

Figure 73: APEJ Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 74: APEJ Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026 

Figure 75: China Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 76: India Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 77: ASEAN Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 78: Australia Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 79: Rest of APEJ Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 80: APEJ Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026 

Figure 81: APEJ Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026 

Figure 82: APEJ Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026 

Figure 83: Japan Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 84: Japan Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026 

Figure 85: Japan Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 86: Japan Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026 

Figure 87: Japan Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026 

Figure 88: Japan Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026 

Figure 89: MEA Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016, 2026

Figure 90: MEA Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026 

Figure 91: MEA Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026

Figure 92: Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026 

Figure 93: MEA Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026

Figure 94: MEA Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026 

Figure 95: GCC Countries Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 96: South Africa Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 97: Rest of MEA Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026

Figure 98: MEA Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026 

Figure 99: MEA Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026 

Figure 100: MEA Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026